UNIVERSITY OF MICHIGAN

CELICA, a Michigan partnership with the U.S. DOE, aims to reduce energy bills for low-income communities via community solar. Community solar allows multiple customers to benefit from solar energy, often through off-site arrays. CELICA's phases have included projects with co-op utilities and low-income households, focusing on equity and positive justice outcomes. Despite lacking enabling legislation, Michigan's community solar projects have seen success with state grant funding. New financing options and federal support, like the Greenhouse Gas Reduction Fund, further bolster community solar initiatives.

Ascentage Pharma announced that APG-2449, a FAK/ALK/ROS1 TKI, has been cleared by China's NMPA to enter two Phase III studies for NSCLC patients resistant to second-generation ALK TKIs and treatment-naïve ALK-positive NSCLC patients.

Ascentage Pharma announced that APG-2449, a FAK/ALK/ROS1 TKI, has been cleared by China's NMPA to enter two Phase III studies for NSCLC patients resistant to or naïve to ALK TKIs. APG-2449 showed preliminary efficacy and safety, with potential to inhibit brain metastases, addressing unmet needs in NSCLC treatment.

Benjamin Pockros, MD, MBA, discusses implementing prostate MRI without contrast in active surveillance protocols, highlighting financial benefits and reduced treatment side effects. At the University of Michigan, they've begun offering this MRI variant for active surveillance patients and plan to study its impact.

Engineered nonpathogenic E. coli displaying decoy-resistant IL18 show potent anti-tumor responses, boosting CAR-NK cell therapy and demonstrating safety in hard-to-treat tumors.

Engineered nonpathogenic E. coli expressing immune-activating cytokines on their surfaces demonstrated potent anti-tumor responses and enhanced CAR-NK cell therapy efficacy, with a 50-60% cure rate in mice, suggesting potential as a 'tumor GPS' for NK cells.

FDA grants 510(k) clearance for an automated Monte Carlo dosimetry method, enabling rapid radiotherapy dose planning in seconds via the MIM SurePlan MRT platform. This advancement allows for quicker, more accurate patient-specific dosimetry, potentially improving radiopharmaceutical therapy outcomes.

GE HealthCare's MIM Software received FDA 510(k) clearance for Monte Carlo dosimetry using the Dose Planning Method (DPM) in MIM SurePlan MRT, enabling fast, accurate absorbed dose calculation for personalized Theranostics treatments without additional hardware.

GE HealthCare’s MIM Software received FDA 510(k) clearance for Monte Carlo dosimetry, enabling accurate radionuclide absorbed dose calculations in theranostics, enhancing personalized cancer care.